Abstract:
:Background: Immunotherapy has revolutionized the treatment of cancer, but this has not come without a cost. Although immune checkpoint inhibitors are less toxic than conventional chemotherapy, they are associated with more frequent autoimmune side effects. Case presentation: We report a case of a patient with metastatic renal cell carcinoma who was treated with nivolumab and subsequently developed treatment related hypothyroidism with consequent rhabdomyolysis. Treatment with thyroxine resulted in resolution of the symptoms. Because of normal thyroid function tests before initiating nivolumab therapy and the absence of any other causes of hypothyroidism, it was safe to extrapolate a causal relationship between nivolumab and hypothyroidism. To date, this is the first reported case of a programmed cell death-1 inhibitor causing hypothyroidism, severe enough to induce rhabdomyolysis. Conclusion: Patients on nivolumab and other PD-1 inhibitors should be monitored and screened regularly for immune-related adverse events.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Abushalha K,Abulaimoun S,Silberstein PTdoi
10.2217/imt-2020-0053subject
Has Abstractpub_date
2020-06-01 00:00:00pages
625-628issue
9eissn
1750-743Xissn
1750-7448journal_volume
12pub_type
杂志文章相关文献
Immunotherapy文献大全abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2019-0191
更新日期:2020-02-01 00:00:00
abstract::Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0031
更新日期:2016-11-01 00:00:00
abstract::Immunotherapy holds a highly promising treatment approach for metastatic melanoma patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor reactive lymphocytes and their reinfusion into lymphodepleted patients, accompanied by IL-2 administration. ACT with tumor-infiltrating T lymph...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.12.143
更新日期:2013-01-01 00:00:00
abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.09.39
更新日期:2009-09-01 00:00:00
abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0134
更新日期:2017-12-01 00:00:00
abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.5
更新日期:2011-03-01 00:00:00
abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0006
更新日期:2020-08-01 00:00:00
abstract::There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0051
更新日期:2017-09-01 00:00:00
abstract::Only a minority of studies addressing the association between immune-related adverse events (IrAE) and outcome considered the immortal time bias, with conflicting results. PubMed, Embase, Web of Science and Scopus were searched through 2 January 2020. Studies reporting the impact of IrAE on outcome in patients treated...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0179
更新日期:2021-02-01 00:00:00
abstract::After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0029
更新日期:2017-06-01 00:00:00
abstract::Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.85
更新日期:2010-01-01 00:00:00
abstract:AIM:This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE:To evaluate four maintenance doses of the allergoid preparation v...
journal_title:Immunotherapy
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2217/imt-2018-0087
更新日期:2018-09-01 00:00:00
abstract::Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0181
更新日期:2020-12-01 00:00:00
abstract::Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2015-0025
更新日期:2016-06-01 00:00:00
abstract::Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.13.155
更新日期:2014-01-01 00:00:00
abstract::Renal toxicity from immune checkpoint inhibitors (ICIs) is an increasingly recognized cause of acute kidney injury among patients with cancer. ICI-associated acute kidney injuries typically present as acute interstitial nephritis and the timing of onset is highly variable. Herein, we present a case of a patient with r...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0223
更新日期:2021-03-01 00:00:00
abstract::The human IgG2 monoclonal antibody tremelimumab is an immune checkpoint inhibitor that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The therapeutic response of anti-CTLA-4 monoclonal antibodies possess unique kinetics, in that antitumor responses are often observed after initial short-term disease prog...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.15.89
更新日期:2016-01-01 00:00:00
abstract::Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0075
更新日期:2020-09-01 00:00:00
abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.5
更新日期:2012-03-01 00:00:00
abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.117
更新日期:2011-10-01 00:00:00
abstract::Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.68
更新日期:2010-11-01 00:00:00
abstract::Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/1750743X.1.2.187
更新日期:2009-03-01 00:00:00
abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.20
更新日期:2012-04-01 00:00:00
abstract::The neonatal phase is a transitory period characterized by an absence of memory cells, favoring a slow adaptive response prone to tolerance effects and the development of Th2-type responses. However, when appropriately stimulated, neonates may achieve an immune response comparable with adult counterparts. One strategy...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.38
更新日期:2009-09-01 00:00:00
abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0188
更新日期:2021-01-01 00:00:00
abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.47
更新日期:2013-07-01 00:00:00
abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.17
更新日期:2013-04-01 00:00:00
abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0020
更新日期:2017-06-01 00:00:00
abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0165
更新日期:2018-08-01 00:00:00
abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.68
更新日期:2013-08-01 00:00:00